Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of down syndrome

Biological Psychiatry

Volumn 75, Issue 3, 2014, Pages 179-188

  Dang, Van ^a,b   Medina, Brian ^b   Das, Devsmita ^b   Moghadam, Sarah ^b   Martin, Kara J ^b   Lin, Bill ^b   Naik, Priyanka ^b   Patel, Devan ^b   Nosheny, Rachel ^a   Wesson Ashford, John ^a,b   Salehi, Ahmad ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

2 adrenergic receptors; Alzheimer's disease; Down syndrome; formoterol; locus coeruleus; norepinephrine; Ts65Dn

Indexed keywords

BETA ADRENERGIC RECEPTOR; FIBROBLAST GROWTH FACTOR; FORMOTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; AUTOPSY; BEHAVIOR; BRAIN ATROPHY; CELL PROLIFERATION; COGNITION; CONTROLLED STUDY; DENDRITIC CELL; DENTATE GYRUS; DOWN SYNDROME; FEAR; GENE EXPRESSION; HIPPOCAMPUS; HYPERACTIVITY; LEARNING; MALE; MEMORY; MICROGLIA; MOUSE; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY FUNCTION;

ALZHEIMER'S DISEASE; DOWN SYNDROME; FORMOTEROL; LOCUS COERULEUS; NOREPINEPHRINE; TS65DN; Β2 ADRENERGIC RECEPTORS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CELL PROLIFERATION; DENDRITES; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ETHANOLAMINES; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NADOLOL; NEURONS; NEUROPEPTIDES; RECEPTORS, ADRENERGIC, BETA-2; SYNAPTOPHYSIN;

EID: 84891624989     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.05.024     Document Type: Article

References (62)

1. T. Hassold, and P. Hunt To err (meiotically) is human: The genesis of human aneuploidy Nat Rev Genet 2 2001 280 291 (Pubitemid 33674776)
2. S.E. Parker, C.T. Mai, M.A. Canfield, R. Rickard, Y. Wang, and R.E. Meyer et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006 Birth Defects Res A Clin Mol Teratol 88 2010 1008 1016
3. R.J. Stancliffe, K.C. Lakin, S.A. Larson, J. Engler, S. Taub, and J. Fortune et al. Demographic characteristics, health conditions, and residential service use in adults with Down syndrome in 25 U.S. states Intellect Dev Disabil 50 2012 92 108
4. K.E. Wisniewski, H.M. Wisniewski, and G.Y. Wen Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome Ann Neurol 17 1985 278 282 (Pubitemid 15136603)
5. K.A. Alford, A. Slender, L. Vanes, Z. Li, E.M. Fisher, and D. Nizetic et al. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome Blood 115 2010 2928 2937
6. P.V. Belichenko, A.M. Kleschevnikov, E. Masliah, C. Wu, R. Takimoto-Kimura, and A. Salehi et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome J Comp Neurol 512 2009 453 466
7. A.M. Kleschevnikov, P.V. Belichenko, A.J. Villar, C.J. Epstein, R.C. Malenka, and W.C. Mobley Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome J Neurosci 24 2004 8153 8160 (Pubitemid 39280835)
8. A. Mitra, M. Blank, and D.V. Madison Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome Brain Res 1440 2012 1 8
9. A. Salehi, B. Pohlman, and W.C. Mobley Down Syndrome/Trisomy 21 L.R. Squire, The New Encyclopedia of Neuroscience 2008 Elsevier San Diego
10. A. Duchon, M. Raveau, C. Chevalier, V. Nalesso, A.J. Sharp, and Y. Herault Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: Relevance for modeling Down syndrome Mamm Genome 22 2011 674 684
11. S.J. Sara The locus coeruleus and noradrenergic modulation of cognition Nat Rev Neurosci 10 2009 211 223
12. M. Millan Sanchez, S.N. Heyn, D. Das, S. Moghadam, K.J. Martin, and A. Salehi Neurobiological elements of cognitive dysfunction in Down syndrome: Exploring the role of APP Biol Psychiatry 71 2012 403 409
13. D.M. Mann, P.O. Yates, B. Marcyniuk, and C.R. Ravindra Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age J Ment Defic Res 29 1985 125 135 (Pubitemid 15029018)
14. A. Salehi, M. Faizi, D. Colas, J. Valletta, J. Laguna, and R. Takimoto-Kimura et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome Sci Transl Med 1 2009 7ra17
15. J. Lockrow, H. Boger, G. Gerhardt, G. Aston-Jones, D. Bachman, and A.C. Granholm A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model J Alzheimers Dis 23 2011 471 489
16. H. Kaufmann, C. Mathias, P. Low, I. Biaggioni, and R. Freeman Experience with droxidopa (NortheraTM) in a phase III multinational, placebo-controlled, parallel group, induction-design study to assess clinical benefit and safety in subjects with neurogenic orthostatic hypotension Clin Auton Res 20 2010 289 330
17. J.B. Aimone, J. Wiles, and F.H. Gage Computational influence of adult neurogenesis on memory encoding Neuron 61 2009 187 202
18. A.P. Nicholas, V.A. Pieribone, and T. Hokfelt Cellular localization of messenger RNA for beta-1 and beta-2 adrenergic receptors in rat brain: An in situ hybridization study Neuroscience 56 1993 1023 1039 (Pubitemid 23308657)
19. M.E. Gibbs, and R.J. Summers Contrasting roles for beta1, beta2 and beta3-adrenoceptors in memory formation in the chick Neuroscience 131 2005 31 42 (Pubitemid 40170486)
20. S. Li, M. Jin, D. Zhang, T. Yang, T. Koeglsperger, and H. Fu et al. Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ Oligomers Neuron 77 2013 929 941
21. Q. Yang, S.A. Rasmussen, and J.M. Friedman Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study Lancet 359 2002 1019 1025 (Pubitemid 34286539)
22. J.G. Baker The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors Br J Pharmacol 160 2010 1048 1061
23. C. LaForce, B.M. Prenner, K. Andriano, C. Lavecchia, and U. Yegen Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma J Asthma 42 2005 101 106 (Pubitemid 40575747)
24. H. Sasaki, H. Kamimura, Y. Shiobara, Y. Esumi, M. Takaichi, and T. Yokoshima Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs Xenobiotica 12 1982 803 812 (Pubitemid 13195149)
25. E.N. McNamee, K.M. Ryan, E.W. Griffin, R.E. Gonzalez-Reyes, K.J. Ryan, and A. Harkin et al. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: Implications for neurodegeneration Brain Behav Immun 24 2010 660 671
26. J.B. Lecaillon, G. Kaiser, M. Palmisano, J. Morgan, and G. Della Cioppa Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer Eur J Clin Pharmacol 55 1999 131 138 (Pubitemid 29196266)
27. M. Faizi, P.L. Bader, C. Tun, A. Encarnacion, A. Kleschevnikov, and P. Belichenko et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer Neurobiol Dis 43 2011 397 413
28. R.M. Escorihuela, A. Fernandez-Teruel, I.F. Vallina, C. Baamonde, M.A. Lumbreras, and M. Dierssen et al. A behavioral assessment of Ts65Dn mice: A putative Down syndrome model Neurosci Lett 199 1995 143 146
29. N.F. Ruby, F. Fernandez, P. Zhang, J. Klima, H.C. Heller, and C.C. Garner Circadian locomotor rhythms are normal in Ts65Dn "Down syndrome" mice and unaffected by pentylenetetrazole J Biol Rhythms 25 2010 63 66
30. M. Incerti, L. Toso, J. Vink, R. Roberson, C. Nold, and D. Abebe et al. Prevention of learning deficit in a Down syndrome model Obstet Gynecol 117 2011 354 361
31. M.E. Coussons-Read, and L.S. Crnic Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: Altered behavior in the elevated plus maze and open field Behav Genet 26 1996 7 13 (Pubitemid 26073018)
32. M.T. Heneka, F. Nadrigny, T. Regen, A. Martinez-Hernandez, L. Dumitrescu-Ozimek, and D. Terwel et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine Proc Natl Acad Sci U S A 107 2010 6058 6063
33. H.K. Kimelberg Receptors on astrocytes - what possible functions? Neurochem Int 26 1995 27 40
34. K.F. Tanaka, H. Kashima, H. Suzuki, K. Ono, and M. Sawada Existence of functional beta1- and beta2-adrenergic receptors on microglia J Neurosci Res 70 2002 232 237
35. R. Pascual, S.P. Zamora-Leon, and A. Valero-Cabre Effects of postweaning social isolation and re-socialization on the expression of vasoactive intestinal peptide (VIP) and dendritic development in the medial prefrontal cortex of the rat Acta Neurobiol Exp (Wars) 66 2006 7 14
36. T. Kiyota, K.L. Ingraham, M.T. Jacobsen, H. Xiong, and T. Ikezu FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders Proc Natl Acad Sci U S A 108 2011 E1339 E1348
37. W. Bondareff, C.Q. Mountjoy, and M. Roth Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia Neurology 32 1982 164 168 (Pubitemid 12223999)
38. H. Braak, D.R. Thal, E. Ghebremedhin, and K. Del Tredici Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years J Neuropathol Exp Neurol 70 2011 960 969
39. T.A. Milner, P. Shah, and J.P. Pierce beta-adrenergic receptors primarily are located on the dendrites of granule cells and interneurons but also are found on astrocytes and a few presynaptic profiles in the rat dentate gyrus Synapse 36 2000 178 193 (Pubitemid 30252993)
40. M. Dierssen, I.F. Vallina, C. Baamonde, S. Garcia-Calatayud, M.A. Lumbreras, and J. Florez Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome Brain Res 749 1997 238 244 (Pubitemid 27104205)
41. C. Baamonde, C. Martinez-Cue, J. Florez, and M. Dierssen G-protein-associated signal transduction processes are restored after postweaning environmental enrichment in Ts65Dn, a Down syndrome mouse model Dev Neurosci 33 2011 442 450
42. J.C. Vis, M.G. Duffels, M.M. Winter, M.E. Weijerman, J.M. Cobben, and S.A. Huisman et al. Down syndrome: A cardiovascular perspective J Intellect Disabil Res 53 2009 419 425
43. B.E. Sekerel, U.M. Sahiner, M. Can, G. Abali, D. Alehan, and K. Aytemir The effects of inhaled formoterol on the autonomic nervous system in adolescents with asthma Ann Allergy Asthma Immunol 107 2011 266 272
44. E.N. McNamee, E.W. Griffin, K.M. Ryan, K.J. Ryan, S. Heffernan, and A. Harkin et al. Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex Neuropharmacology 59 2010 37 48
45. K.P. Mayfield, D. Soszynski, W. Kozak, A. Kozak, K. Rudolph, and M.J. Kluger Beta-adrenergic receptor subtype effects on stress fever and thermoregulation Neuroimmunomodulation 6 1999 305 317 (Pubitemid 29305609)
46. C.F. Murchison, X.Y. Zhang, W.P. Zhang, M. Ouyang, A. Lee, and S.A. Thomas A distinct role for norepinephrine in memory retrieval Cell 117 2004 131 143 (Pubitemid 38469904)
47. S. Busquets, M.T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, and E. Ametller et al. Anticachectic effects of formoterol: A drug for potential treatment of muscle wasting Cancer Res 64 2004 6725 6731 (Pubitemid 39297935)
48. R.A. Bartow, and R.N. Brogden Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma Drugs 55 1998 303 322 (Pubitemid 28081632)
49. G. Bensch, R.J. Lapidus, B.E. Levine, W. Lumry, U. Yegen, and P. Kiselev et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler Ann Allergy Asthma Immunol 86 2001 19 27 (Pubitemid 32104566)
50. G. Pollonini, V. Gao, A. Rabe, S. Palminiello, G. Albertini, and C.M. Alberini Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn Neuroscience 156 2008 99 106
51. C. Raineki, P.J. Holman, J. Debiec, M. Bugg, A. Beasley, and R.M. Sullivan Functional emergence of the hippocampus in context fear learning in infant rats Hippocampus 20 2010 1037 1046
52. L. Kaczmarek Expression of c-fos and other genes encoding transcription factors in long-term potentiation Behav Neural Biol 57 1992 263 266
53. A. Contestabile, T. Fila, C. Ceccarelli, P. Bonasoni, L. Bonapace, and D. Santini et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice Hippocampus 17 2007 665 678 (Pubitemid 47292037)
54. A. Contestabile, T. Fila, A. Cappellini, R. Bartesaghi, and E. Ciani Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome Cell Prolif 42 2009 171 181
55. L. Chakrabarti, J. Scafidi, V. Gallo, and T.F. Haydar Environmental enrichment rescues postnatal neurogenesis defect in the male and female Ts65Dn mouse model of Down syndrome Dev Neurosci 33 2011 428 441
56. S. Clark, J. Schwalbe, M.R. Stasko, P.J. Yarowsky, and A.C. Costa Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome Exp Neurol 200 2006 256 261 (Pubitemid 44080763)
57. A. Contestabile, T. Fila, R. Bartesaghi, and E. Ciani Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases J Neurochem 97 2006 515 526
58. K.L. Goodison, I.M. Parhad, C.L. White 3rd, A.A. Sima, and A.W. Clark Neuronal and glial gene expression in neocortex of Down's syndrome and Alzheimer's disease J Neuropathol Exp Neurol 52 1993 192 198 (Pubitemid 23136017)
59. G. Zdaniuk, T. Wierzba-Bobrowicz, G.M. Szpak, and T. Stepien Astroglia disturbances during development of the central nervous system in fetuses with Down's syndrome Folia Neuropathol 49 2011 109 114
60. A. Mallei, B. Shi, and I. Mocchetti Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons Mol Pharmacol 61 2002 1017 1024 (Pubitemid 34441766)
61. P. Follesa, and I. Mocchetti Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system Mol Pharmacol 43 1993 132 138 (Pubitemid 23055055)
62. J.O. Edgin, G.M. Mason, M.J. Allman, G.T. Capone, I. Deleon, and C. Maslen et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome J Neurodev Disord 2 2010 149 164